drugset
drugset / Trial / NCT03331250

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

NCT03331250 ↗

Phase 2 Active not recruiting 13 enrolled Massachusetts General Hospital Eisai Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin

Timeline

Start
2018-01-18
Primary completion
2023-07-21
Completion
2026-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Eribulin Small molecule — Intravenous

Indications

angiosarcoma epithelioid hemangioendothelioma